Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot
dc.contributor.author | Alexander, J. H. | en_US |
dc.contributor.author | Dyke, C. K. | en_US |
dc.contributor.author | Yang, H. | en_US |
dc.contributor.author | Becker, R. C. | en_US |
dc.contributor.author | Hasselblad, V. | en_US |
dc.contributor.author | Zillman, L. A. | en_US |
dc.contributor.author | Kleiman, N. S. | en_US |
dc.contributor.author | Hochman, J. S. | en_US |
dc.contributor.author | Berger, P. B. | en_US |
dc.contributor.author | Cohen, E. A. | en_US |
dc.contributor.author | Lincoff, A. Michael | en_US |
dc.contributor.author | Saint-Jacques, H. | en_US |
dc.contributor.author | Chetcuti, S. | en_US |
dc.contributor.author | Burton, J. R. | en_US |
dc.contributor.author | Buergler, J. M. | en_US |
dc.contributor.author | Spence, F. P. | en_US |
dc.contributor.author | Shimoto, Y. | en_US |
dc.contributor.author | Robertson, T. L. | en_US |
dc.contributor.author | Kunitada, S. | en_US |
dc.contributor.author | Bovill, E. G. | en_US |
dc.contributor.author | Armstrong, P. W. | en_US |
dc.contributor.author | Harrington, R. A. | en_US |
dc.date.accessioned | 2010-06-01T21:27:31Z | |
dc.date.available | 2010-06-01T21:27:31Z | |
dc.date.issued | 2004-02 | en_US |
dc.identifier.citation | Alexander, J. H.; Dyke, C. K.; Yang, H.; Becker, R. C.; Hasselblad, V.; Zillman, L. A.; Kleiman, N. S.; Hochman, J. S.; Berger, P. B.; Cohen, E. A.; Lincoff, A. M.; Saint-Jacques, H.; Chetcuti, S.; Burton, J. R.; Buergler, J. M.; Spence, F. P.; Shimoto, Y.; Robertson, T. L.; Kunitada, S.; Bovill, E. G.; Armstrong, P. W.; Harrington, R. A. (2004). "Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot." Journal of Thrombosis and Haemostasis 2(2): 234-241. <http://hdl.handle.net/2027.42/74517> | en_US |
dc.identifier.issn | 1538-7933 | en_US |
dc.identifier.issn | 1538-7836 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74517 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14995984&dopt=citation | en_US |
dc.description.abstract | Background : Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI). Objectives : To investigate drug levels achieved, effect on coagulation markers, and preliminary efficacy and safety of several doses of DX-9065a, an intravenous, small molecule, direct, reversible FXa inhibitor during PCI. Patients and methods : Patients undergoing elective, native-vessel PCI ( n = 175) were randomized 4 : 1 to open-label DX-9065a or heparin in one of four sequential stages. DX-9065a regimens in stages I–III were designed to achieve concentrations of > 100 ng mL −1 , > 75 ng mL −1 , and > 150 ng mL −1 . Stage IV used the stage III regimen but included patients recently given heparin. Results : At 15 min median (minimum) DX-9065a plasma levels were 192 (176), 122 (117), 334 (221), and 429 (231) ng mL −1 in stages I–IV, respectively. Median whole-blood international normalized ratios (INRs) were 2.6 (interquartile range 2.5, 2.7), 1.9 (1.8, 2.0), 3.2 (3.0, 4.1), and 3.8 (3.4, 4.6), and anti-FXa levels were 0.36 (0.32, 0.38), 0.33 (0.26, 0.39), 0.45 (0.41, 0.51), and 0.62 (0.52, 0.65) U mL −1 , respectively. Stage II enrollment was stopped ( n = 7) after one serious thrombotic event. Ischemic and bleeding events were rare and, in this small population, showed no clear relation to DX-9065a dose. Conclusions : Elective PCI is feasible using a direct FXa inhibitor for anticoagulation. Predictable plasma drug levels can be rapidly obtained with double-bolus and infusion DX-9065a dosing. Monitoring of DX-9065a may be possible using whole-blood INR. Direct FXa inhibition is a novel and potentially promising approach to anticoagulation during PCI that deserves further study. | en_US |
dc.format.extent | 113655 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | © 2004 International Society on Thrombosis and Haemostasis | en_US |
dc.subject.other | Angioplasty | en_US |
dc.subject.other | Anticoagulant | en_US |
dc.subject.other | Factor Xa Inhibition | en_US |
dc.title | Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | †† University of Michigan, Ann Arbor, MI, USA; | en_US |
dc.contributor.affiliationother | Duke University Medical Center and | en_US |
dc.contributor.affiliationother | Duke Clinical Research Institute, Durham, NC, USA; | en_US |
dc.contributor.affiliationother | † Baylor College of Medicine and the Methodist-DeBakey Heart Center, Houston, TX, USA; | en_US |
dc.contributor.affiliationother | † St Luke's-Roosevelt Medical Center, New York, NY, USA; | en_US |
dc.contributor.affiliationother | § Mayo Clinic Foundation, Rochester, MN, USA; | en_US |
dc.contributor.affiliationother | ¶ Sunnybrook & Women's College Health Science Center, Toronto, Ontario, Canada; | en_US |
dc.contributor.affiliationother | The Cleveland Clinic Foundation, Cleveland, OH, USA; | en_US |
dc.contributor.affiliationother | †† University of Alberta, Edmonton, Alberta, Canada; | en_US |
dc.contributor.affiliationother | §§ Foothills Hospital, Calgary, Alberta, Canada; | en_US |
dc.contributor.affiliationother | ¶¶ Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan; and | en_US |
dc.contributor.affiliationother | University of Vermont Medical Center, Burlington, VT, USA | en_US |
dc.identifier.pmid | 14995984 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74517/1/j.1538-7933.2004.00594.x.pdf | |
dc.identifier.doi | 10.1111/j.1538-7933.2004.00594.x | en_US |
dc.identifier.source | Journal of Thrombosis and Haemostasis | en_US |
dc.identifier.citedreference | Smith SC, Dove JT, Jacobs AK, Kennedy JW, Keriakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO. ACC/ AHA Guidelines for Percutaneous Coronary Intervention. J Am Coll Cardiol 2001; 37: 2239i – lxvi. | en_US |
dc.identifier.citedreference | Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: 321S – 36S. | en_US |
dc.identifier.citedreference | Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575 – 82. | en_US |
dc.identifier.citedreference | Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331 – 42. | en_US |
dc.identifier.citedreference | Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619 – 25. | en_US |
dc.identifier.citedreference | 6 REMBRANDT Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000; 102: 2726 – 31. | en_US |
dc.identifier.citedreference | Coussement PK, Bassand JP, Convens C, Vrolix J, Boland G, Grollier R, Michels A, Vahanian M, Vanderheyden H, Rupprecht J, Van de Werf F for the PENTALYSE investigators. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: PENTALYSE study. Eur Heart J 2001; 22: 1716 – 24. | en_US |
dc.identifier.citedreference | Rezaie AR. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost 2003; 89: 112 – 21. | en_US |
dc.identifier.citedreference | Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease. Circulation 2002; 105: 2382 – 8. | en_US |
dc.identifier.citedreference | Yamazaki M, Asakura H, Aoshima K, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Ikeda T, Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost 1994; 72: 392 – 6. | en_US |
dc.identifier.citedreference | Rogers KL, Chi L, Rapundalo ST, Kramer JB, Gallagher KP. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol 1999; 94: 15 – 22. | en_US |
dc.identifier.citedreference | Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC. DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996; 276: 1030 – 8. | en_US |
dc.identifier.citedreference | Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92: 485 – 91. | en_US |
dc.identifier.citedreference | Kim DI, Kambayashi J, Shibuya T, Sakon M, Kawasaki T. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft. J Atheroscler Thromb 1996; 2: 110 – 6. | en_US |
dc.identifier.citedreference | Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733 – 8. | en_US |
dc.identifier.citedreference | Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31 – 41. | en_US |
dc.identifier.citedreference | Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis JD, Lambrew CT, Leiboff R, Mann KG, Markis JF, Fratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 1991; 115: 256 – 65. | en_US |
dc.identifier.citedreference | Piantadosi S. Sample size and power. In: Clinical Trials: a Methodological Perspective. New York: Wiley-Interscience, 1997: 148 – 83. | en_US |
dc.identifier.citedreference | Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189 – 98. | en_US |
dc.identifier.citedreference | Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochmann JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. Management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Available at: http://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm Accessed 4 June 2003. | en_US |
dc.identifier.citedreference | Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch E, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853 – 63. | en_US |
dc.identifier.citedreference | Moliterno DJ, Mukherjee D. Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. Am Heart J 2000; 140: S136 – 42. | en_US |
dc.identifier.citedreference | Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S – 94S. | en_US |
dc.identifier.citedreference | Kereiakes DJ, Montalescot G, Antman EM, Cohen M, Darius H, Ferguson JJ, Grines C, Karsch KR, Kleiman NS, Moliterno DJ, Steg PG, Teirstein P, Van de Werf F, Wallentin L. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002; 144: 615 – 24. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.